Calculation method of patent term extension of Chinese innovative medicineGENG Wen-jun, DING Jin-xi2641-2646
Research on the legal definition of rare diseases and drugs and devices for rare diseasesYANG Dian-zheng, XU Wen-xiu, LI Zhuang-qi, YANG Yue2647-2653
Research on post-marketing drug risk management measures of FDA and its implication for China:a case of thalidomideCHEN Jin-min, LIU Peng-cheng, YU Zheng2654-2659
Pharmacological and clinical evaluation of calaspargase pegol-mknl-a L-asparaginase specific enzymeYANG Xue, NI Qian, LI Ting, PEI Yi-fang, LI Shao-qiang2660-2663
General considerations on bio-waiver using quality assessment of azacitidine injectionCHEN Ai-ping, HE Wu2664-2667
Research progress in the determination of free concentration of antibacterial drugsWU A-long, XU Bing-fa2672-2676
Research progress of bevacizumab in the treatment of ovarian cancerGUO Chong-zhen, QU Lian-yue, DU Rong-rong, YAN Cheng-da, LIN Jian-yang2677-2682
Advances of dermato-pharmacokinetic in the bioequivalence assessment of topical formulationLIU Xiao-lin, DING Liang, GUAN Yan-ping, HUANG Min, ZHONG Guo-ping2683-2689
The role of a new generation of TKI ripretinib in gastrointestinal stromal tumor treatment and its research progressZHANG Yi-wen, PAN Zong-fu, YE Qiang, LIU Yu-jia, SUN Jiao, LI Li, HUANG Ping2690-2694